![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DTL |
Gene summary for DTL |
![]() |
Gene information | Species | Human | Gene symbol | DTL | Gene ID | 51514 |
Gene name | denticleless E3 ubiquitin protein ligase homolog | |
Gene Alias | CDT2 | |
Cytomap | 1q32.3 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q9NZJ0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51514 | DTL | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 7.01e-03 | 1.30e-01 | 0.0208 |
51514 | DTL | CCI_1 | Human | Cervix | CC | 1.61e-10 | 6.83e-01 | 0.528 |
51514 | DTL | CCI_2 | Human | Cervix | CC | 3.32e-03 | 4.78e-01 | 0.5249 |
51514 | DTL | CCI_3 | Human | Cervix | CC | 3.50e-06 | 5.61e-01 | 0.516 |
51514 | DTL | CCII_1 | Human | Cervix | CC | 1.61e-02 | 1.44e-01 | 0.3249 |
51514 | DTL | C04 | Human | Oral cavity | OSCC | 6.33e-06 | 3.26e-01 | 0.2633 |
51514 | DTL | C21 | Human | Oral cavity | OSCC | 9.02e-19 | 6.42e-01 | 0.2678 |
51514 | DTL | C30 | Human | Oral cavity | OSCC | 1.26e-09 | 5.57e-01 | 0.3055 |
51514 | DTL | C38 | Human | Oral cavity | OSCC | 3.61e-03 | 3.76e-01 | 0.172 |
51514 | DTL | C43 | Human | Oral cavity | OSCC | 2.80e-05 | 1.51e-01 | 0.1704 |
51514 | DTL | C46 | Human | Oral cavity | OSCC | 1.00e-07 | 2.07e-01 | 0.1673 |
51514 | DTL | C57 | Human | Oral cavity | OSCC | 1.02e-04 | 2.02e-01 | 0.1679 |
51514 | DTL | LN22 | Human | Oral cavity | OSCC | 2.01e-02 | 3.55e-01 | 0.1733 |
51514 | DTL | LN46 | Human | Oral cavity | OSCC | 2.17e-04 | 2.62e-01 | 0.1666 |
51514 | DTL | SYSMH3 | Human | Oral cavity | OSCC | 7.95e-06 | 2.95e-01 | 0.2442 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:19019922 | Cervix | CC | positive regulation of mitotic cell cycle phase transition | 26/2311 | 93/18723 | 3.97e-05 | 6.18e-04 | 26 |
GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
GO:19019892 | Cervix | CC | positive regulation of cell cycle phase transition | 28/2311 | 115/18723 | 2.82e-04 | 3.07e-03 | 28 |
GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
GO:1902751 | Cervix | CC | positive regulation of cell cycle G2/M phase transition | 11/2311 | 30/18723 | 5.71e-04 | 5.45e-03 | 11 |
GO:0010971 | Cervix | CC | positive regulation of G2/M transition of mitotic cell cycle | 10/2311 | 27/18723 | 9.25e-04 | 7.84e-03 | 10 |
GO:00448392 | Cervix | CC | cell cycle G2/M phase transition | 31/2311 | 148/18723 | 2.07e-03 | 1.51e-02 | 31 |
GO:00457862 | Cervix | CC | negative regulation of cell cycle | 67/2311 | 385/18723 | 2.21e-03 | 1.59e-02 | 67 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DTL | SNV | Missense_Mutation | rs557642530 | c.2093C>T | p.Pro698Leu | p.P698L | Q9NZJ0 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DTL | SNV | Missense_Mutation | novel | c.599N>T | p.Pro200Leu | p.P200L | Q9NZJ0 | protein_coding | tolerated(0.46) | benign(0.013) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DTL | SNV | Missense_Mutation | novel | c.607N>G | p.Lys203Glu | p.K203E | Q9NZJ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.506) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
DTL | SNV | Missense_Mutation | c.230N>A | p.Arg77Gln | p.R77Q | Q9NZJ0 | protein_coding | tolerated(0.06) | benign(0.173) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
DTL | SNV | Missense_Mutation | novel | c.1999G>A | p.Ala667Thr | p.A667T | Q9NZJ0 | protein_coding | deleterious(0.01) | benign(0.231) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DTL | SNV | Missense_Mutation | novel | c.83T>G | p.Leu28Arg | p.L28R | Q9NZJ0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
DTL | SNV | Missense_Mutation | c.959A>C | p.Tyr320Ser | p.Y320S | Q9NZJ0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-49-6767-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DTL | SNV | Missense_Mutation | novel | c.1378N>G | p.Leu460Val | p.L460V | Q9NZJ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.609) | TCGA-62-A471-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
DTL | SNV | Missense_Mutation | c.394N>A | p.Leu132Met | p.L132M | Q9NZJ0 | protein_coding | deleterious(0.02) | possibly_damaging(0.528) | TCGA-22-5472-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD | |
DTL | SNV | Missense_Mutation | c.1662N>C | p.Arg554Ser | p.R554S | Q9NZJ0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-39-5024-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |